Top

International Journal of Clinical Oncology

Published in:

01-04-2010 | Original Article

¹⁸F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer

Authors: Keiichi Jingu, Tomohiro Kaneta, Kenji Nemoto, Ken Takeda, Yoshihiro Ogawa, Hisanori Ariga, Masashi Koto, Toru Sakayauchi, Yoshihiro Takai, Shoki Takahashi, Shogo Yamada

Published in: International Journal of Clinical Oncology | Issue 2/2010

Abstract

Objectives

The objectives of this study were to reveal the utility of ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) within 7 days after chemoradiotherapy to predict prognosis in patients with postoperative recurrent esophageal cancer.

Materials and methods

Patients scheduled to undergo concurrent chemoradiotherapy for postoperative locoregional recurrence of esophageal cancer were recruited. Selection criteria were: (1) locoregional recurrence, (2) no previous radiation therapy, (3) planning treatment with concurrent chemoradiotherapy, (4) FDG-PET performed <2 weeks before chemoradiotherapy, and (5) no serious diabetes. FDG-PET was performed <7 days after chemoradiotherapy. No more treatment after chemoradiotherapy was given until disease progression was diagnosed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Correlations of FDG-PET findings with cause-specific survival and local control rates were investigated prospectively.

Results

Twenty patients were enrolled. Median observation period of patients who survived was 45.0 months. Median maximum standardized uptake value (SUV_max) after chemoradiotherapy was 2.4, and median SUV_max before chemoradiotherapy was 8.4. Cause-specific survival and local control rates were significantly better for patients with SUV_max ≤ 2.4 after chemoradiotherapy (log-rank test, P = 0.033 and 0.010, respectively). SUV_max before chemoradiotherapy tended to be correlated only with cause-specific survival rate (log-rank test, P = 0.076). Change in metabolic activity of FDG was significantly correlated with local control rate (log-rank test, P = 0.042).

Conclusions

FDG-PET performed even <7 days after chemoradiotherapy predicts prognosis in patients with postoperative recurrent esophageal cancer.

Flamen P, Lerut A, Van Cutsem E et al (2000) The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120:1085–1092CrossRefPubMed

Kato H, Miyazaki T, Nakajima M et al (2004) Value of positron emission tomography in the diagnosis of recurrent oesohageal carcinoma. Br J Surg 91:1004–1009CrossRefPubMed

Duong CP, Demitriou H, Weih L et al (2006) Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging 33:759–769CrossRefPubMed

Kato H, Kuwano H, Nakajima M et al (2002) Comparison between positron emission tomography and computed tomography in the use of assessment of esophageal carcinoma. Cancer 94:921–928CrossRefPubMed

Fukunaga T, Okazumi S, Koide Y et al (1998) Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 39:1002–1007PubMed

Blackstock AW, Farmer MR, Lovato J et al (2006) A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 64:455–460PubMed

Swisher SG, Erasmus J, Maish M et al (2004) 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 15:1776–1785CrossRef

Downey RJ, Akhurst T, Ilson D et al (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21:428–432CrossRefPubMed

Brucher BL, Weber W, Bauer M et al (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233:300–309CrossRefPubMed

10.

Nishimura Y, Koike R, Nakamatsu K et al (2003) Concurrent chemoradiotherapy with protracted infusion of 5-FU and Cisplatin for postoperative recurrent or residual esophageal cancer. Jpn J Clin Oncol 33:341–345CrossRefPubMed

11.

Raoul JL, Le Prise E, Meunier B et al (1995) Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 37:174–176CrossRefPubMed

12.

Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133:24–31CrossRefPubMed

13.

Nemoto K, Ariga H, Kakuto Y et al (2001) Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol 61:165–168CrossRefPubMed

14.

Nemoto K, Matsushita H, Ogawa Y et al (2003) Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am J Clin Oncol 26:46–49CrossRefPubMed

15.

Yamanaka H, Motohiro T, Michiura T et al (1998) Nedaplatin and 5-FU combined with radiation in treatment for esophageal cancer. Jpn J Thorac Cardiovasc Surg 10:943–948

16.

Jingu K, Nemoto K, Matsushita H et al (2006) Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer 6:50CrossRefPubMed

17.

Kubota R, Yamada S, Kubota K et al (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972–1980PubMed

18.

Kubota K, Yokoyama J, Yamaguchi K et al (2004) FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 31:590–595CrossRefPubMed

19.

Kato H, Kuwano H, Nakajima M et al (2002) Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184:279–283CrossRefPubMed

20.

Schmidt M, Bollschweiler E, Dietlein M et al (2009) Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 36:735–744CrossRefPubMed

21.

Lodge MA, Lucas JD, Marsden PK et al (1999) A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26:22–30CrossRefPubMed

22.

Nakamoto Y, Higashi T, Sakahara H et al (2000) Delayed (18)F-fluoro-2-deoxy-d-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89:2547–2554CrossRefPubMed

23.

Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412–1417PubMed

24.

Matthies A, Hickeson M, Cuchiara A et al (2002) Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871–875PubMed

25.

Ma SY, See LC, Lai CH C et al (2003) Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 44:1775–1783PubMed

26.

Yen TC, Chang YC, Chan SC et al (2005) Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging 32:541–548CrossRefPubMed

27.

Flamen P, Van Cutsem E, Lerut A et al (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361–368CrossRefPubMed

28.

Kostakoglu L, Goldsmith SJ (2004) PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 45:56–68PubMed

29.

Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065PubMed

30.

Wieder HA, Brucher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900–908CrossRefPubMed

Title: 18F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer
Authors: Keiichi Jingu
Tomohiro Kaneta
Kenji Nemoto
Ken Takeda
Yoshihiro Ogawa
Hisanori Ariga
Masashi Koto
Toru Sakayauchi
Yoshihiro Takai
Shoki Takahashi
Shogo Yamada
Publication date: 01-04-2010
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0044-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2010

Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor

Isolated gastric metastasis from renal cell carcinoma 19 years after radical nephrectomy

PSK may suppress CD57+ T cells to improve survival of advanced gastric cancer patients

Huge pedunculated angiomyofibroblastoma of the vulva

Primary Ewing’s sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin

Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer